65,437 trials
Episodic Migraine
Primary: Number of Participants Who Completed Initially Assigned Treatment and Achieved at Least a 50% Reduction From Baseline in Monthly Migraine Days at Month 12 — 232; 35…
Solid Tumors
Primary: The Number of Participants Experiencing Drug-Related Grade 3-4 Adverse Events (AEs) — 1; 1; 0; 0 Participants
Glioblastoma · Grade IV Astrocytoma · Glioblastoma Multiforme
Primary: Overall Survival (OS) — 10.2; 11.64 months
Diabetic Macular Edema
Primary: Vascular Endothelial Growth Factor Levels — 73.46 pg/ml
Gastroenteritis Norovirus
Primary: Time to Initial Clinical Resolution of Norovirus Symptoms — 19; 11 days — p=0.459
Pruritus · Atopic Dermatitis
Primary: Reduction of Itching in AD — 1.70; 1.55 score on a scale
Human Immunodeficiency Virus
Primary: The Safety of Dapivirine (25 mg) Administered Via a Silicone Vaginal Ring in HIV-uninfected Adolescent Females, When Inserted Once Every 4 Weeks During 24 Weeks of Study…
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) — -3.53; -3.54 score on a scale
Cataract · Presbyopia
Primary: Mean Binocular Photopic Uncorrected Intermediate (66 cm) Visual Acuity (UCIVA) — 0.051; 0.228 logMAR — p=<.0001
Breast Cancer
Primary: Diarrhea for >= 2 Consecutive Days — 68; 69.6; 65.2; 72.2 percentage of patients
Aortic Aneurysm, Thoracic, Chronic Type B Dissection
Primary: 30 Day Composite Safety Endpoint — 10.0 percentage of participants
Acute Graft Versus Host Disease
Primary: Number of Participants With Complete Response (CR) — 34 Participants
Oral Squamous Cell Carcinoma
Primary: Determine an Efficacious Dose (mg/cm2) of PRV111 (Cisplatin Transmucosal System) Via Number of Tumor Responses — 7 Participants
EBV-induced Lymphomas · EBV-associated Malignancies · Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
Primary: Objective Response Rate (ORR) — 68.0; 50.0; 16.0; 14.3 Percentage of participants
Aerosol Containment · Aerosol Generating Procedure
Primary: Particle Count Measurements During Intubation — 4026; 411; 105; 392 particles/cm^3 — p=<0.001